Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Azacitidine + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Azacitidine||Vidaza||azacytidine|CC-486|5-azacytidine|5-AC|U-18496|Onureg||DNMT inhibitor (Pan) 5||Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome and Onureg (azacitidine) is FDA approved for use in continued treatment of acute myeloid leukemia(FDA.gov).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03161223||Phase Ib/II||Durvalumab + Romidepsin Azacitidine + Durvalumab Azacitidine + Durvalumab + Romidepsin Durvalumab + Pralatrexate + Romidepsin||Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma||Recruiting||USA||0|
|NCT02775903||Phase II||Azacitidine Azacitidine + Durvalumab||An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)||Completed||USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT||3|
|NCT02811497||Phase II||Azacitidine + Durvalumab||Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)||Completed||CAN||0|
|NCT02281084||Phase II||Azacitidine Azacitidine + Durvalumab||Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes||Active, not recruiting||USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS||1|
|NCT02117219||Phase I||Azacitidine + Durvalumab||Phase 1 Study to Evaluate MEDI4736 in MDS||Completed||USA | GBR | FRA | DEU||0|